New hope in the fight against cancer

Thanks to a history of clinical trials research, people with cancer are living longer and with a better quality of life than ever before. Cancer research is advancing at a fast pace and, as a result, researchers are able to develop targeted therapies that are changing the standards of care and saving lives.

Some patients may fear that enrollment in a clinical trial means they may receive no treatment at all. The reality is that patients in studies receive either the best treatment currently known for their specific cancer, or a new, and possibly more effective, therapy. Placebos are never used in place of treatment when an existing therapy exists.

Lancaster General Cancer Center participates in numerous studies sponsored by the National Cancer Institute through groups such as the Eastern Cooperative Oncology Group, the Radiation Therapy Oncology Group and the American College of Surgeons Oncology Group.

Lancaster General is a member of the University of Pennsylvania Cancer Center Network.

Current oncology treatment trials open for participation:

Site	Sponsor	Study Title
Brain
RTOG0825	RTOG	Phase III Double-Blind Placebo-Controlled Trial Of Conventional Concurrent Chemoradiation And Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation And Adjuvant Temozolomide In Patients With Newly Diagnosed Glioblastoma
Breast
AVF4349n VIRGO	GENENTECH	An Observational study of Treatment Patterns and Safety Outcomes for Metastatic or Local Recurrent Breast Cancer
E5103	ECOG	A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
PACCT-1	ECOG	Program for the Assessment of Clinical Cancer Tests: Trial Assigning Individualized Options for Treatment: The TAILORx Trial
Z1071	ACOSOG	A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial Diagnosis
GI
C80405	CALGB	A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum **Cetuximab provided**
R-04	NSABP	A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum
GU
E2804	ECOG	E2804 -The Best Trial: A Randomized Phase II study of VEGF, RAF Kinase, mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib, Temsirolimus in Advanced Renal Cell Carcinoma
E2805	ECOG	Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
Heme
CML Registry	NOVARTIS	A Worldwide, Observational Registry collecting Longitudinal Data on the management of Chronic Myelogenous Leukemia (CML) patients (The WORLD CML Registry) in routine practice
Lung
E4508	ECOG	Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-Small Cell Lung Cancer Patients Who Will Not Receive Bevacizumab-based Therapy
Melanoma
E1697	ECOG	Phase III Randomized Study of Four Weeks High Dose IFN-"2b in Stage T3 - T4 or N1 (microscopic) Melanoma
Myeloma
S0777	SWOG	Randomized Phase III trial of Lenalidomide and low dose dexamethasone (LDD) VS Bortezomab, Lenalidomide and low dose dexamethasone  for induction in patients with previously untreated Multiple Myeloma without an intent for immediate autologous Stem Cell transplant

Updated 3-18-2010.